{"url_path":"/sec/antx/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1880438/0001193125-26-344549-index.html","accession_number":"0001193125-26-344549","cik":"0001880438","ticker":"ANTX","issuer_name":"AN2 Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1880438/0001193125-26-344549-index.html","primary_entity_key":"0001880438","primary_entity_name":"AN2 Therapeutics, Inc."},"word_count":82,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n \n\n[Press Release of AN2 Therapeutics Inc. dated August 11, 2026](antx-ex99_1.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nAN2 Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nAugust 11, 2026\n\nBy:\n\n/s/ Eric Easom\n\n \n\n \n\n \n\nEric Easom\nChief Executive Officer\n(Principal Executive Officer)"}